Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

OBJECTIVE: To estimate the budget impact of introducing avelumab as a second-line (2L) treatment option for patients with locally advanced or metastatic urothelial cancer (mUC) from the perspective of a US third-party payer (commercial and Medicare). METHODS: A budget impact model (BIM) with a three...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clinicoecon Outcomes Res
Autors principals: Kongnakorn, Thitima, Bharmal, Murtuza, Kearney, Mairead, Phatak, Hemant, Benedict, Agnes, Bhanegaonkar, Abhijeet, Galsky, Matthew
Format: Artigo
Idioma:Inglês
Publicat: Dove 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6850681/
https://ncbi.nlm.nih.gov/pubmed/31807039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S215069
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars